<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859453</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1617-QLG-BCG</org_study_id>
    <nct_id>NCT03859453</nct_id>
  </id_info>
  <brief_title>Follow-up in Early and Locally Advanced Breast Cancer Patients</brief_title>
  <official_title>Follow-up in Early and Locally Advanced Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cross-sectional follow-up study of Early and Locally Advanced Breast Cancer patients after&#xD;
      primary treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess follow-up patterns and identify patients with&#xD;
      increased levels of physical and/or psychosocial problems after treatment in early breast&#xD;
      cancer and locally advanced breast cancer.&#xD;
&#xD;
      830 patients stratified by cancer sites and treatment - a minimum of 120 patients within each&#xD;
      stratum - will be recruited.&#xD;
&#xD;
      Institutional data on follow-up policy, demographic and clinical data (related to treatment&#xD;
      history and tumor characteristics) will be collected. Patients will complete a set of 139&#xD;
      Quality of Life questions, at one single time point.&#xD;
&#xD;
      Statistical analysis includes descriptive statistic for socio-demographic and clinical data,&#xD;
      overall and per treatment, age and risk group. Patterns of follow-up will be identified and&#xD;
      described overall, and per treatment, age, risk group and country.&#xD;
&#xD;
      Where available, normative data will be used to identify those QoL domains where there is a&#xD;
      clinically relevant difference with the general population.&#xD;
&#xD;
      Multivariable model building will be used to build predictive models on the overall&#xD;
      population to investigate determinants for the physical, sexual and emotional needs based on&#xD;
      the identified PROM outcomes. Factor analysis will be undertaken to investigate the&#xD;
      inter-correlations between physical, sexual and emotional needs in the overall population and&#xD;
      in the relevant subgroups of interest.&#xD;
&#xD;
      The magnitude of the observed differences will be assessed by clinical important effect size&#xD;
      rather than by statistical significance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>18 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC QLQ-C30 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>18 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC-QLQ-BR-45 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>18 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC OUT-PATSAT-C7 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>18 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered EORTC Sexual Health Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>18 months after first patient inclusion</time_frame>
    <description>It will be evaluated using self-administered Distress Thermometer</description>
  </primary_outcome>
  <enrollment type="Anticipated">830</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        EBC and LABC cancer patients after primary treatment attending participating hospitals for&#xD;
        routine follow-up.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven Early Breast Cancer (EBC) and Locally Advanced Breast Cancer&#xD;
             (LABC) patients who have completed their primary treatment (except endocrine therapy),&#xD;
             between 12 months and 36 months after the diagnosis.&#xD;
&#xD;
          -  Disease-free without any evidence of relapse&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Ability to understand and fill out questionnaires.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic breast cancer (defined as secondary spread to other organs, such as bones,&#xD;
             lung, liver, mediastinal lymph nodes) or DCIS.&#xD;
&#xD;
          -  Other cancer diagnosis in the past 5 years except non-melanotic skin cancer or&#xD;
             cervical intraepithelial neoplasia.&#xD;
&#xD;
          -  Male breast cancer.&#xD;
&#xD;
          -  Patients on maintenance therapy (other than endocrine therapy).&#xD;
&#xD;
          -  Patients participating in interventional clinical studies with Quality of Life as&#xD;
             primary endpoint.&#xD;
&#xD;
          -  Any psychological (including preexisting psychiatric disorders), familial,&#xD;
             sociological or geographical condition potentially hampering compliance with the study&#xD;
             protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>eortc@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig-Klinik fuer Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kuhnt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken - Helios Klinikum Wuppertal - Klin. Univ. Witten / Herdecke</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vesna Bjelic-Radisic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Cretella</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Icro Meattini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Elena Cazzaniga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Serpentini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederieke van Duijnhoven</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elzbieta Senkus-Konefka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Great Poland Cancer Centre</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Kazmierska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Pogoda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amalia Palacios Eito</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Rubio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Fernandez Lizarbe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan I. Arraras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Group Of Private Clinics Hirslanden - Hirslanden Klinik-Tumor Zentrum Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Razvan Popescu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust - St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Hartup</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

